CN106692297B - Composition for assisting in reducing blood sugar and preparation method and application thereof - Google Patents
Composition for assisting in reducing blood sugar and preparation method and application thereof Download PDFInfo
- Publication number
- CN106692297B CN106692297B CN201710080001.5A CN201710080001A CN106692297B CN 106692297 B CN106692297 B CN 106692297B CN 201710080001 A CN201710080001 A CN 201710080001A CN 106692297 B CN106692297 B CN 106692297B
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- extract
- content
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 239000008280 blood Substances 0.000 title claims abstract description 37
- 210000004369 blood Anatomy 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title abstract description 22
- 241000233779 Cyclocarya paliurus Species 0.000 claims abstract description 36
- 244000179886 Moringa oleifera Species 0.000 claims abstract description 31
- 235000011347 Moringa oleifera Nutrition 0.000 claims abstract description 31
- 244000302512 Momordica charantia Species 0.000 claims abstract description 27
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 27
- 239000000843 powder Substances 0.000 claims abstract description 26
- 240000000249 Morus alba Species 0.000 claims abstract description 23
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 23
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims abstract description 19
- 235000013305 food Nutrition 0.000 claims abstract description 16
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 14
- 229930003944 flavone Natural products 0.000 claims abstract description 14
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 14
- 235000011949 flavones Nutrition 0.000 claims abstract description 14
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 150000004676 glycans Chemical class 0.000 claims abstract description 10
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 10
- 239000005017 polysaccharide Substances 0.000 claims abstract description 10
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims abstract description 8
- 235000018365 Momordica dioica Nutrition 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 229930185803 charantin Natural products 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000007902 hard capsule Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 229930003935 flavonoid Natural products 0.000 claims description 3
- 150000002215 flavonoids Chemical class 0.000 claims description 3
- 235000017173 flavonoids Nutrition 0.000 claims description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 3
- 229930182490 saponin Natural products 0.000 claims description 3
- 150000007949 saponins Chemical class 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 17
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 14
- 239000008103 glucose Substances 0.000 abstract description 14
- 235000005911 diet Nutrition 0.000 abstract description 3
- 230000000378 dietary effect Effects 0.000 abstract description 3
- 239000003472 antidiabetic agent Substances 0.000 abstract description 2
- 238000010298 pulverizing process Methods 0.000 abstract description 2
- 238000012827 research and development Methods 0.000 abstract description 2
- 229930182478 glucoside Natural products 0.000 abstract 1
- 150000008131 glucosides Chemical class 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 239000000523 sample Substances 0.000 description 10
- 238000000465 moulding Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 239000010935 stainless steel Substances 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001018563 Nekemias grossedentata Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012547 material qualification Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229930194234 momordicoside Natural products 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- WHGYBXFWUBPSRW-FEYSZYNQSA-N β-dextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)C(O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FEYSZYNQSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a high-efficiency composition for assisting in reducing blood sugar, and a preparation method and application thereof. The composition comprises 400-500 parts by weight of cyclocarya paliurus extract, 200-300 parts by weight of moringa oleifera leaf ultramicro wall-broken fine powder, 120-240 parts by weight of mulberry leaf extract and 80-160 parts by weight of bitter gourd extract. Wherein the cyclocarya paliurus total flavone content is 8-16%, and the polysaccharide content is 12-28%; pulverizing Moringa oleifera leaves by low-temperature airflow to obtain ultramicro wall-broken powder; the content of the total flavone in the mulberry leaf extract is 2 to 15 percent, and the content of DNJ is 1 to 2 percent; the content of the balsam pear extract balsam pear glucoside is 5 to 20 percent. The test shows that: the composition can obviously reduce the blood sugar of a diabetic mouse, can obviously enhance the tolerance of the diabetic mouse to the glucose, and has important significance for the research and development of hypoglycemic drugs, health-care foods, functional common foods, special medical foods and special dietary foods.
Description
Technical Field
The invention relates to a composition for efficiently assisting in reducing blood sugar. In particular to a compatible composition of cyclocarya paliurus extract, ultrafine wall-broken moringa oleifera leaf fine powder, mulberry leaf extract and bitter gourd extract, a preparation method and application thereof.
Technical Field
The global diabetes incidence rate is rapidly increased due to the influence of a plurality of factors such as the continuous improvement of the living standard of people, the change of the dietary structure, the increasingly tense life rhythm, the life style of less movement and more sitting and the like. Statistically, diabetes mellitus becomes the third most serious chronic disease after tumor and cardiovascular and cerebrovascular diseases, which threatens human health. Diabetes is a systemic progressive disease caused by the fact that the blood sugar is out of control and higher than a normal level, 0 complications are many and serious, and clinical treatment mainly comprises oral sulfonylureas and biguanides hypoglycemic drugs except for insulin injection, and has certain side effects and body injury. At present, fewer health-care products for effectively reducing blood sugar and assisting in preventing and treating diabetes are available, and the health-care products are not in accordance with the national policy of 'preventive treatment of disease' major health industry.
Cyclocarya paliurus leaves are new resource food (bulletin number: No. 10 in 2013) approved by the Ministry of health of China, and moringa leaves are new resource food (bulletin number: No. 19 in 2012) approved by the Ministry of health of China. Folium mori and balsam pear are used as the traditional medicine and food homologous substances, the folium mori is used as the traditional Chinese medicine for treating diabetes (namely diabetes in modern medicine) in clinic from ancient times, and the effect of improving the water drinking disease (namely diabetes in modern medicine) by the folium mori is also recorded in Japanese ancient book 'eating tea health preserving record'. In addition, the bitter gourds are used as medicinal plants since ancient times in China, and the bitter gourds are mentioned in ancient documents such as 'saving herbal medicine' and 'compendium of herbal medicine'; in diabetes, it is emphasized that it can "quench thirst" and "treat polydipsia" and so on.
A teabag containing Moringa oleifera leaf and its preparation method (patent application publication No. CN105519721A) disclose a teabag containing Moringa oleifera leaf and its preparation method. The formula comprises 1-2.8 parts of cyclocarya paliurus leaves, 0.1-1.0 part of moringa leaves and 0.1-0.5 part of Liupu tea leaves by mass, the preparation method of the teabag comprises the steps of crushing, mixing, granulating, bagging and the like, and the specification does not relate to extraction of composition substances and technical inspiration of quality control; a method for preparing health-care food able to obviously improve blood sugar and blood fat and quickly supplement the trace elements necessary for human body (patent application publication No. CN105851360A) features that the trace elements necessary for human body are quickly supplemented while the blood sugar and blood fat are obviously improved. The formula of the tea comprises 10-40 parts by weight of Ampelopsis grossedentata leaves, 10-40 parts by weight of cyclocarya paliurus leaves and 10-40 parts by weight of moringa oleifera leaves, and the specification does not refer to technological parameters and quality control technical inspiration.
The invention aims to adopt new resource food raw materials of cyclocarya paliurus leaves and moringa leaves and traditional medicinal and edible homologous mulberry leaves and bitter gourds to form a formula, specific components are enriched by the technical schemes of specific process parameters, raw material qualification, quality control and the like, and the composition for obviously reducing blood sugar is prepared according to a specific proportion. The test proves that the compound has the pharmacological actions of obviously reducing the blood sugar of the diabetic mouse and obviously enhancing the sugar tolerance of the diabetic mouse.
Disclosure of Invention
The invention aims to provide a composition for efficiently assisting in reducing blood sugar and a preparation method thereof. The second purpose is to provide the application of the composition.
The first object of the present invention is achieved by the following technical means.
The composition comprises 400-500 parts by weight of cyclocarya paliurus extract, 200-300 parts by weight of moringa oleifera leaf ultramicro wall-broken fine powder, 120-240 parts by weight of mulberry leaf extract and 60-180 parts by weight of bitter gourd extract.
Preferably, the composition consists of 420-480 parts by weight of cyclocarya paliurus extract, 220-280 parts by weight of moringa oleifera leaf ultramicro wall-broken fine powder, 140-220 parts by weight of mulberry leaf extract and 80-160 parts by weight of bitter gourd extract.
Preferably, the composition comprises 440-460 parts by weight of cyclocarya paliurus extract, 240-260 parts by weight of moringa oleifera leaf ultramicro wall-broken fine powder, 160-200 parts by weight of mulberry leaf extract and 100-140 parts by weight of bitter gourd extract.
Most preferably, the composition consists of 450 parts by weight of cyclocarya paliurus extract, 250 parts by weight of moringa oleifera leaf ultramicro wall-broken fine powder, 180 parts by weight of mulberry leaf extract and 120 parts by weight of bitter gourd extract.
Secondly, the cyclocarya paliurus extract is prepared by taking cyclocarya paliurus leaves as a raw material, extracting the raw material by using 20-40-mesh coarse powder and 70-80% ethanol for 2-3 times (the temperature is controlled at 80 ℃ and the extraction time is 2-4 hours) according to the mass-to-volume ratio (g/ml) of 1:3, collecting an extracting solution, and concentrating the extracting solution under reduced pressure until the relative density is 1.05 (measured at 20 ℃) to obtain a concentrated solution containing flavone and saponin; after weighing the residue, the mass to volume ratio (g/ml) of 1: 8-8.5 decocting and extracting with purified water for 2 times (temperature is controlled at 90 ℃, extraction time is 2-3 h), collecting the extracting solution, and concentrating under reduced pressure until the relative density is 1.23 (measured at 20 ℃) to obtain polysaccharide-containing concentrated solution; mixing the concentrated solutions for 2 times, concentrating, and drying to obtain cyclocarya paliurus extract. The cyclocarya paliurus extract contains 8-16% of total flavonoids and 12-28% of polysaccharides, preferably 14-26% and more preferably 16-24%
Thirdly, the ultrafine moringa oleifera leaf wall-breaking fine powder is prepared by crushing dried moringa oleifera leaves into 800-1200 meshes at the temperature of-20 ℃ and under the condition of liquid nitrogen by adopting a low-temperature airflow crushing technology.
In addition, the mulberry leaf extract and the balsam pear extract are made of food-grade or pharmaceutical raw materials. Wherein, the control indexes of the mulberry leaf extract quality are limited as follows: DNJ content is 1% -2%, and total flavone content is 2% -15%, preferably 4% -12%, more preferably 5% -10%. The bitter gourd extract quality control indexes are limited as follows: the content of the charantin is 5-20%, preferably 8-17%, more preferably 10-15%.
And finally, weighing the cyclocarya paliurus extract, the moringa oleifera leaf ultramicro wall-broken fine powder, the food or medicine grade mulberry leaf extract and the bitter gourd extract in parts by weight and the preferable parts by weight, crushing, sieving by a sieve of 80-100 meshes, and fully stirring and uniformly mixing in a clean stainless steel container to obtain the composition.
The second purpose of the invention is realized by adopting the following technical scheme.
Firstly, the composition can be used in medicines, health-care foods, functional common foods, special medical foods and special dietary foods for assisting in reducing blood sugar.
The composition can be directly prepared into solid oral preparations such as powder, granules, hard capsules and tablets without adding any auxiliary materials, can also be prepared into water pills by taking one or more of water, rice vinegar and the like as an excipient, and can also be further prepared into preparations such as granules, tablets, hard capsules, soft capsules and pills by adding one or more of water, alpha-cyclodextrin, β -cyclodextrin, sodium carboxymethylcellulose, starch, microcrystalline cellulose, povidone, PEG-4000, PEG-6000, magnesium stearate, medicinal or food vegetable oil and the like.
The specific implementation mode is as follows:
the invention is further illustrated by the following specific examples, which are not intended to be limiting in any way, and any variations or alterations based on the teachings of the present invention are intended to be within the scope of the invention.
Example 1: preparation of cyclocarya paliurus extract
Taking cyclocarya paliurus leaves, removing impurities, drying, crushing, and sieving with a 24-mesh sieve. Weighing 10kg of cyclocarya paliurus leaf coarse powder, placing into an extraction tank, adding 75% ethanol with a mass-to-volume ratio (g/ml) of 1:3, extracting under hot reflux for 2 times (temperature controlled at 80 deg.C for 3 hr each time), mixing the two extractive solutions, and concentrating under reduced pressure to relative density of 1.05 (measured at 20 deg.C) to obtain concentrated solution containing flavone and saponin components; and (3) weighing the residual residue after the hot reflux extraction of the ethanol, and adding a mixture of 1: 8 decocting with purified water for 2 times (temperature controlled at 90 deg.C, each time for 2 hr), mixing the 2 extractive solutions, and concentrating under reduced pressure to relative ratio of 1.23 (measured at 20 deg.C) to obtain concentrated solution containing polysaccharide component; mixing the ethanol hot reflux and the water decoction concentrated solution, concentrating and drying to obtain 2.5kg of cyclocarya paliurus extract, and detecting: the content of total flavone is 15%, and the content of polysaccharide is 21%.
Description of the drawings: FIG. 1 is a flow chart of the extraction process of cyclocarya paliurus extract
Example 2: preparation of ultrafine wall-broken moringa oleifera leaf fine powder
Starting a liquid nitrogen gas flow low-temperature pulverizer (high bridge/M-250 type), precooling to-20 ℃, weighing 1.5kg of dried moringa leaves (the water content is less than or equal to 10 percent) and putting the moringa leaves into the pulverizer, starting the pulverizer and pulverizing to 1000 meshes to obtain 1.25kg of the ultramicro fine wall-broken powder of the moringa leaves.
Example 3: preparation of folium Mori extract and fructus Momordicae Charantiae extract
1.5kg of food-grade mulberry leaf extract with the specification of 1:10 is purchased. The content of flavone is 6 percent and the content of DNJ is 1.8 percent.
1kg of food-grade balsam pear extract (Q/HLB031-2013) with the content of momordicoside more than or equal to 10% is purchased. The content of the charantin is 13 percent by self-checking.
Example 4: preparation of the composition 1
400g of cyclocarya paliurus extract prepared in example 1, 300g of moringa oleifera leaf ultramicro wall-breaking fine powder prepared in example 2, 240g of mulberry leaf extract prepared in example 3 and 60g of bitter gourd extract are taken, ground, sieved by a 80-mesh sieve, and fully stirred and uniformly mixed in a clean stainless steel container to obtain 996g of a composition.
Example 5: preparation of the composition 2
420g of cyclocarya paliurus extract prepared in example 1, 280g of moringa oleifera leaf ultramicro wall-breaking fine powder prepared in example 2, 220g of mulberry leaf extract prepared in example 3 and 80g of bitter gourd extract are taken, ground, sieved by a 100-mesh sieve, and fully stirred and uniformly mixed in a clean stainless steel container to obtain 991g of a composition.
Example 6: preparation of the composition 3
450g of cyclocarya paliurus extract prepared in example 1, 250g of fine moringa oleifera leaf wall-breaking powder prepared in example 2, 180g of mulberry leaf extract prepared in example 3 and 120g of bitter gourd extract are taken, ground, sieved by a 80-mesh sieve and fully stirred and uniformly mixed in a clean stainless steel container, and 995g of the composition is obtained.
Example 7: preparation of the composition 4
480g of cyclocarya paliurus extract prepared in example 1, 220g of ultrafine wall-broken fine powder of moringa leaves prepared in example 2, 160g of mulberry leaf extract prepared in example 3 and 140g of bitter gourd extract are taken, ground, sieved by a 100-mesh sieve, and fully stirred and uniformly mixed in a clean stainless steel container to obtain 989g of composition.
Example 8: preparation of the composition 5
Taking 500g of cyclocarya paliurus extract prepared in example 1, 200g of moringa oleifera leaf ultramicro wall-breaking fine powder prepared in example 2, 120g of mulberry leaf extract prepared in example 3 and 180g of bitter gourd extract, crushing, sieving with a 100-mesh sieve, and fully stirring and uniformly mixing in a clean stainless steel container to obtain 993g of the composition.
Example 9: hard capsule preparation
Taking 100g of the composition prepared in example 6, carrying out wet granulation, drying and filling to obtain the hard capsule for assisting in reducing blood sugar.
Example 10: preparation of watered pill
100g of the composition prepared in example 7 is taken, and purified water and rice vinegar are adopted as excipients to prepare water-bindered pills for assisting in reducing blood sugar.
Example 11: preparation of granules
200g of the composition prepared in the embodiment 6 is taken, and a proper amount of starch, sodium carboxymethyl cellulose and β -dextrin are added, and the mixture is made into soft materials by a wet method, extruded and sieved, dried and granulated to prepare the granules for assisting in reducing blood sugar.
Example 12: tablet preparation
200g of the composition prepared in example 6 is taken, and a proper amount of starch, povidone and magnesium stearate are added, and the tablets for assisting in reducing blood sugar are prepared by wet granulation, drying and tabletting.
To further illustrate the technical effects of the composition of the present invention, the composition prepared in example 7 (prepared by mixing 200g of cyclocarya paliurus extract, 500g of fine moringa leaf ultramicro wall-broken powder, 60g of mulberry leaf extract and 240g of balsam pear extract) in the proportions of the cyclocarya paliurus extract prepared in example 1, the moringa leaf ultramicro wall-broken powder prepared in example 2, the mulberry leaf extract and the balsam pear extract prepared in example 3 and the four non-invention combination are selected as control samples, the numbers are ①, ②, ③, ④ and ⑤ in sequence, the composition prepared in example 6 is selected as a test sample, the number is ⑥, diabetes pills (Xiaoke Pill, XKP, Guangzhou Chinese medicine factory) are selected as positive control drugs, a blank control group and a model control group are simultaneously set to eliminate molding interference and errors, and a mouse glucose-lowering test and a glucose tolerance test are simultaneously carried out, and the results are as follows:
test animals and devices: healthy Kunming male mice (body weight 26 + -2 g); 5% alloxan water solution (new formula), blood sugar determination kit (used according to the instruction), full-automatic biochemical detector, 721-B type ultraviolet spectrophotometer.
Sample administration dosage, namely, 60kg of adult human sample administration dosage of the composition (test sample ⑥) is determined to be 7 g/day, the daily sample administration dosage of a control sample ⑤ is determined to be 1.05g/kg BW according to an equal dose sample administration comparable principle by converting the daily mouse sample administration dosage to be 1.05g/kg BW., the daily sample administration dosage of the positive control group thirst-eliminating pills is determined to be 1.05g/kg BW. according to an equal dose sample administration comparable principle by combining the daily highest recommended dosage of the thirst-eliminating pills (Xiaoke Pill, XKP, Guangzhou Chinese medicine factory), and the daily recommended dosages of the control samples ① to ④ are determined to be 1.05g/kg BW according to the equal dose sample administration comparable principle by combining the national pharmacopoeia or related industry standards.
Molding and grouping, namely selecting 400 healthy Kunming male mice, randomly selecting 20 mice as a blank group (NC), and using the rest 380 mice as molding machines, before molding, fasting all animals for 48h (free drinking water), injecting 80 mg/kg BW alloxan into the tail veins of 380 molding mice (iv), injecting equal doses of physiological saline into the blank group, recovering to feed 30s after injection, normally feeding for 5 days, fasting for 5h, collecting blood from the orbital veins of 380 molding mice, collecting blood by EDTA anticoagulation and centrifugation, measuring the fasting blood glucose value, and selecting 320 mice with blood glucose higher than 13mmol/L as hyperglycemic molding success animals for test, wherein the mice are successfully molded, and selecting 320 mice from the mice to randomly divide into 8 groups (2 repeats in each group, 20 repeats) and dividing into a model group (TNB), a thirst-eliminating pill positive control group (XKP) and a test group (① - ⑥).
And (3) fasting blood glucose reduction experiment, namely, carrying out continuous experiment for 6 weeks by respectively carrying out intragastric gavage on ① - ⑥ samples of 1.05g/kg BW in a test group every day, carrying out intragastric gavage on XKP1.05g/kg BW in a positive control group every day, carrying out intragastric gavage on TNB and NC groups every day and carrying out isopyknic distilled water (fasting is for 5 hours before intragastric gavage), weighing and measuring fasting blood glucose after intragastric gavage on the last day of each week, wherein the test results are.
Sugar tolerance test: after 6 weeks of continuous test, the last fasting blood glucose was collected as the blood glucose level at 0 h. The groups were then separately perfused with 2g/kg BW of gastric glucose solution, blood was collected from orbital veins of mice 0.5, 1, 2 hours after the administration of glucose, and the blood glucose values were measured separately, with the test results shown in Table 3.
Table 1: results of measurement of body weight of test mouse
Table 2: test result of fasting blood glucose of mouse
Table 3: test results of sugar tolerance in mice
Note that in tables 1-3, there was no significant difference in blood glucose values among 2 replicates in the TNB group, XKP group, ① - ⑥ group, which were combined at the time of statistics.
Tables 1-3 show that at the end of the test, the mice in the ⑥ group have high statistical difference (P < 0.01) in the weight, fasting blood sugar value and sugar tolerance measurement results compared with the TNB group and the ① - ⑤ group, and the mice in the ⑥ group have statistical difference (P < 0.05) in the weight, fasting blood sugar value and sugar tolerance measurement results compared with the XKP group.
In conclusion, the composition can remarkably improve the weight loss of experimental diabetic mice, quickly reduce fasting blood glucose and remarkably enhance the glucose tolerance. The pharmacological activity of the compound is superior to that of a positive control drug, namely the diabetes pill, and the compound has extremely important significance for research and development of auxiliary hypoglycemic health food and diabetes prevention and treatment drugs.
The attached drawings are as follows:
Claims (6)
1. the composition comprises 400-500 parts by weight of cyclocarya paliurus extract with total flavone content of 8-16% and polysaccharide content of 12-28%, 200-300 parts by weight of moringa oleifera leaf ultrafine wall breaking fine powder crushed to 800-1200 meshes at liquid nitrogen and-20 ℃ by adopting a low-temperature airflow crushing technology, 120-240 parts by weight of mulberry leaf extract with DNJ content of 1-2%, total flavone content of 2-15% and 60-180 parts by weight of bitter gourd extract with charantin content of 5-20%.
2. The composition of claim 1, wherein: the composition comprises 420-480 parts by weight of cyclocarya paliurus extract with 8-16% of total flavonoids and 14-26% of polysaccharides, and is prepared by adopting a low-temperature airflow crushing technology to crush 220-280 parts by weight of 800-1200-mesh moringa oleifera leaf ultramicro wall breaking fine powder at liquid nitrogen and-20 ℃, 140-220 parts by weight of mulberry leaf extract with 1-2% of DNJ content and 4-12% of total flavonoids and 80-160 parts by weight of bitter gourd extract with 8-17% of charantin.
3. The composition of claim 1, wherein: the composition comprises 440-460 parts by weight of cyclocarya paliurus extract with total flavone content of 8-16% and polysaccharide content of 16-24%, 240-260 parts by weight of 800-1200-mesh moringa oleifera leaf ultramicro wall breaking fine powder prepared by adopting a low-temperature airflow crushing technology and crushing at-20 ℃ in liquid nitrogen, 160-200 parts by weight of mulberry leaf extract with DNJ content of 1-2%, total flavone content of 5-10% and 100-140 parts by weight of balsam pear extract with charantin content of 10-15%.
4. The composition of claim 1, wherein: the composition comprises 450 parts by weight of cyclocarya paliurus extract with 8-16% of total flavone content and 16-24% of polysaccharide content, 250 parts by weight of 800-1200-mesh moringa oleifera leaf ultramicro wall breaking fine powder prepared by adopting a low-temperature airflow crushing technology and crushing at-20 ℃ and liquid nitrogen, 180 parts by weight of mulberry leaf extract with 1-2% of DNJ content and 5-10% of total flavone content, and 120 parts by weight of bitter gourd extract with 10-15% of charantin content.
5. The composition according to any one of claims 1 to 4, wherein: the cyclocarya paliurus extract is prepared by taking cyclocarya paliurus leaves as a raw material, crushing the cyclocarya paliurus leaves into 20-40 meshes, performing hot reflux extraction for 2-3 times by adopting ethanol with the mass-volume ratio g/ml of 1:3 and the concentration of 70-80%, controlling the temperature at 80 ℃, extracting for 2-4 hours, collecting an extracting solution, concentrating the extracting solution under reduced pressure to 20 ℃, and determining the relative density at 1.05 to obtain a concentrated solution containing flavone and saponin; after weighing the residue, adding a mixture of 1: 8-8.5 decocting and extracting with purified water for 2 times, controlling the temperature at 90 ℃, extracting for 2-3 hours, collecting an extracting solution, and concentrating under reduced pressure to obtain a polysaccharide-containing concentrated solution with the relative density of 1.23 measured at 20 ℃; mixing the concentrated solutions for 2 times, concentrating, and drying to obtain cyclocarya paliurus extract.
6. The composition according to any one of claims 1 to 4, wherein: the composition is applied to medicines for assisting in reducing blood sugar, and is a health-care food for assisting in reducing blood sugar in a functional orientation; optionally adding medicinal and health food acceptable adjuvants, and further making into powder, tablet, granule, hard capsule, soft capsule, and watered pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710080001.5A CN106692297B (en) | 2017-02-15 | 2017-02-15 | Composition for assisting in reducing blood sugar and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710080001.5A CN106692297B (en) | 2017-02-15 | 2017-02-15 | Composition for assisting in reducing blood sugar and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106692297A CN106692297A (en) | 2017-05-24 |
| CN106692297B true CN106692297B (en) | 2020-03-31 |
Family
ID=58909144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710080001.5A Active CN106692297B (en) | 2017-02-15 | 2017-02-15 | Composition for assisting in reducing blood sugar and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106692297B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107136269B (en) * | 2017-06-29 | 2020-09-15 | 北京颐方生物科技有限公司 | Cyclocarya paliurus and bitter gourd blood sugar reducing tea and preparation method thereof |
| CN109966417A (en) * | 2017-12-28 | 2019-07-05 | 随州市万松堂康汇保健品有限公司 | A kind of solid beverage for diabetic population |
| CN108283285A (en) * | 2017-12-31 | 2018-07-17 | 深圳市金乐智能健康科技有限公司 | A kind of health-care physiotherapeutic food of diabetes |
| CN108935842A (en) * | 2018-06-28 | 2018-12-07 | 华南农业大学 | A kind of preparation and application of balsam pear blue or green money willow lipid-lowering health-care tea |
| CN109463685A (en) * | 2018-11-22 | 2019-03-15 | 河南农业大学 | A kind of preparation method and health care product of woody hypoglycemic composition |
| CN109875047A (en) * | 2019-04-04 | 2019-06-14 | 云南农业大学 | A kind of wheaten food auxiliary additive for alleviating anorectal disease |
| CN110051726A (en) * | 2019-04-16 | 2019-07-26 | 浙江大学 | The preparation method and application of general flavone and total starches in a kind of Qingqian Willow leaf |
| CN112352895A (en) * | 2020-11-02 | 2021-02-12 | 辽宁康汇医学临床研究有限公司 | Angelica keiskei plant herbaceous solid beverage assisting in reducing blood sugar and preparation method thereof |
| CN112569300A (en) * | 2020-12-29 | 2021-03-30 | 深圳可弘生物科技有限公司 | Composition and preparation for reducing blood sugar, preparation method and application thereof |
| CN112970923A (en) * | 2021-04-19 | 2021-06-18 | 广州王老吉餐饮管理发展有限公司 | Plant extract for flavoring syrup |
| CN118285504B (en) * | 2024-06-05 | 2024-09-17 | 内蒙古蒙牛乳业（集团）股份有限公司 | Plant extract with bacterial source dipeptidyl peptidase-4 inhibitory activity and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101744888A (en) * | 2008-12-08 | 2010-06-23 | 文燕 | Cyclocarya paliurus leaf composition |
-
2017
- 2017-02-15 CN CN201710080001.5A patent/CN106692297B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101744888A (en) * | 2008-12-08 | 2010-06-23 | 文燕 | Cyclocarya paliurus leaf composition |
Non-Patent Citations (2)
| Title |
|---|
| 降血糖活性成分苦瓜皂苷的纯化工艺研究;张柏瑀等;《中国现代中药》;20080531;第10卷(第5期);第18-20页 * |
| 青钱柳降血糖功能因子研究概况;吴凡等;《光明中医》;20141031;第29卷(第10期);第2245-2247页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106692297A (en) | 2017-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106692297B (en) | Composition for assisting in reducing blood sugar and preparation method and application thereof | |
| EP2520305A1 (en) | Medicinal composition including sunflower extract, preparative method and use thereof | |
| CN102626484A (en) | Medicine compound for treating subacute thyroiditis | |
| CN100469377C (en) | Nankang soft capsule for treating prostatitis | |
| CN108785412B (en) | Composition with function of improving sleep and preparation method thereof | |
| CN109078132B (en) | Composition with blood sugar reducing function or auxiliary blood sugar reducing function and preparation method and application thereof | |
| CN114209758A (en) | Traditional Chinese medicine compound composition capable of maintaining blood sugar health level and preparation method and application thereof | |
| CN112385841A (en) | Medicated diet composition for type 2 diabetes and preparation method thereof | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN110960569A (en) | Phyllanthus emblica extract and preparation method and application thereof | |
| CN101185738A (en) | Gynaecologic inflammation rehabilitation effervescence granular preparation and confecting method thereof | |
| CN115137770A (en) | Preparation method of traditional Chinese medicine product with efficacy of reducing blood fat and blood pressure | |
| CN108498563B (en) | Chitosan composition and preparation method thereof | |
| CN102485263B (en) | Medicinal composition for treating chronic cough of children and its preparation method | |
| CN101991722B (en) | Shiqi exogenous traditional Chinese medicine capsule | |
| WO2010037255A1 (en) | The usage of ginseng and gynostemma pentaphyllum compound preparation in manufacture of medicaments with the effects of lipid regulation and blood-sugar regulation | |
| CN101269123A (en) | Secondary development novel technique for thirst eliminating capsule for lowering blood sugar | |
| CN112316013A (en) | Composition containing guava and tylophora fruits and application thereof | |
| CN106466396B (en) | Gynaecologic menstruation regulating sustained-release dropping pill and preparation method thereof | |
| CN104940428B (en) | Hypoglycemic composition containing wolfberry fruits and application thereof | |
| CN110585358B (en) | Application of sorghum bran total flavonoids in preventing and treating gout diseases | |
| CN110898170B (en) | Traditional Chinese medicine composition for treating metabolic syndrome and preparation thereof | |
| CN109364206A (en) | The preparation method and applications of Xingbei Zhike granules active site | |
| CN102145113B (en) | Chinese medical composition capable of resolving phlegm and relieving asthma and preparation method thereof | |
| CN102225082A (en) | Medicament for preventing and treating diabetes and complications thereof and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |